Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Medarex, a biopharmaceutical company, has announced that it will receive a $1 million milestone payment from its partner, MedImmune, a biopharmaceutical company, for the allowance of an investigational new drug application for MEDI-546, a fully human antibody that targets a component of the type 1 interferon pathway.
Subscribe to our email newsletter
MEDI-546 will be studied in patients with scleroderma, a chronic autoimmune disease characterized by hardening and thickening of the skin and other organs.
MedImmune has previously entered into collaboration with Medarex to focus on two specific antibodies, MDX-1103 (now known as MEDI-545) and MDX-1333 (now known as MEDI-546).
Under the terms of the agreement, MedImmune is responsible for all ongoing clinical development activities. Prior to the beginning of pivotal studies, Medarex may elect to co-develop the products in return for the opportunity to co-promote and to receive a share of the commercial profits in the US. In all other cases, Medarex will be entitled to receive milestone payments and royalties.
Howard Pien, chairman and CEO of Medarex, said: This investigational new drug application marks the second antibody targeting the interferon inflammatory pathway that MedImmune has supported for advancement into the clinic using our UltiMAb technology.